Abstract Number: 1231 • 2013 ACR/ARHP Annual Meeting
The Quality Of Life and Resource Use Related To Hip Fractures Based On Data From The International Costs and Utilities Related To Osteoporotic Fractures Study
Background/Purpose: The International Costs and Utilities Related to Osteoporotic fractures Study (ICUROS) is an ongoing 18 months prospective observational study with the objective of estimating…Abstract Number: 1232 • 2013 ACR/ARHP Annual Meeting
Osteoporosis In Rheumatoid Arthritis – Still a Threat In The Biologic Era?
Background/Purpose: Osteoporosis is a well-known extra articular manifestation in rheumatoid arthritis (RA). In RA biologic disease modifying anti rheumatic drugs (DMARDs) has been shown to…Abstract Number: 1233 • 2013 ACR/ARHP Annual Meeting
Strontium Ranelate Uncouples Bone Resorption From Bone Formation In Osteoporotic Patients With Or Without Clinical Risk Factors
Background/Purpose: Strontium ranelate has proven efficacy against vertebral and nonvertebral fractures in postmenopausal osteoporosis. We explored whether the effect of strontium ranelate on bone turnover…Abstract Number: 1234 • 2013 ACR/ARHP Annual Meeting
Effects Of Biological Therapy In Bone Metabolism In Patients With Chronic Inflammatory Arthropathies
Background/Purpose: The efficacy of biological agents in the treatment of chronic inflammatory arthropathies is well known, however, the effect of this therapy in bone metabolism…Abstract Number: 1194 • 2013 ACR/ARHP Annual Meeting
Enhanced IL-1β and IL-6 Production In Gout Patients Upon Stimulation With Mono Sodium Urate Crystals and Synergizing Agents Compared To Healthy Volunteers
Background/Purpose: Gout is an autoinflammatory disease characterized by the deposition of monosodium urate (MSU) crystals in the joints of hyperuricaemic patients and subsequent attacks of…Abstract Number: 1195 • 2013 ACR/ARHP Annual Meeting
Sex Differences In Gout Evaluation and Management
Background/Purpose: Little is known regarding the evaluation, characteristics and management of women with gout. To characterize potential gender differences, we therefore compared clinical manifestations and…Abstract Number: 1196 • 2013 ACR/ARHP Annual Meeting
Chronic Renal Injury Does Not Prevent Achievement Of Target Serum Uric Acid In Tophaceous Gout
Background/Purpose: ACR 2012 management guidelines for tophaceous gout (TG) recommend urate lowering therapies (ULT) to achieve a target serum uric acid (SUA) of < 6.0…Abstract Number: 1197 • 2013 ACR/ARHP Annual Meeting
Gout Medications and The Risk For Incident Coronary Heart Disease and Stroke: The Framingham Heart Study
Background/Purpose: Recent studies suggest a protective association between both urate lowering medications and colchicine and the risk for coronary heart disease. The goal of the…Abstract Number: 1198 • 2013 ACR/ARHP Annual Meeting
Allopurinol Dose Above Creatinine Clearance Based Dose Is Safe and Effective in Gout – Compliance, Efficacy and Safety At 2 and 3 Years
Background/Purpose: Gout is a common form of inflammatory arthritis caused by the crystallisation of uric acid. Sustained reduction of SU below 6mg/dl is critical for…Abstract Number: 1199 • 2013 ACR/ARHP Annual Meeting
The Performance Of a Novel Scoring System In The Differential Diagnosis Between Acute Gout and Septic Arthritis
Background/Purpose: Recently, a novel scoring system was developed for the diagnosis of gout without joint fluid analysis (1). The performance of this scoring system in the…Abstract Number: 1202 • 2013 ACR/ARHP Annual Meeting
Two Family Kindreds With Blau’s Syndrome Associated With Unusual NOD2 Mutations
Background/Purpose: The aim of this study was to report families of Blau’s syndrome with unusual NOD2 gene variants. Methods: Two proband patients were seen, and their clinical…Abstract Number: 1200 • 2013 ACR/ARHP Annual Meeting
Proportion Of Patients Achieving Serum Urate Target In a Longitudinal Veterans Administration (VA) Gout Registry: Crystal Registry
Background/Purpose: Gout is the most common inflammatory arthritis managed by healthcare providers at the VA Healthcare System. CRYSTAL registry is a longitudinal observational study at…Abstract Number: 1201 • 2013 ACR/ARHP Annual Meeting
A Progress Report On An Emerging Disease: NOD2-Associated Autoinflammatory Disease
Background/Purpose: We recently reported a new disease designated as NOD2-associated autoinflammatory disease (NAID). The aim of this study was to update the progress on defining the disease. Methods: A…Abstract Number: 1203 • 2013 ACR/ARHP Annual Meeting
An Escalating Dose Of Anakinra In Patients With Autoinflammatory Disease Is a Safe and Reasonable Therapeutic Option
Background/Purpose: The autoinflammatory diseases are diseases in which there is seemingly unprovoked stimulation of the innate immune system. The enhanced release of cytokines in…Abstract Number: 1204 • 2013 ACR/ARHP Annual Meeting
Model-Based Pharmacokinetics Of Canakinumab and Pharmacodynamics Of IL-1Beta Binding In Cryopyrin Associated Periodic Syndromes, a Step Towards Personalized Medicine
Background/Purpose: Cryopyrin-associated periodic syndrome (CAPS), comprises of extremely rare, inherited auto-inflammatory diseases, including the mildest form familial cold auto-inflammatory syndrome (FCAS), the more severe Muckle-Wells…